Last quarter (Q ), Lexington Biosciences's total revenue was C$―, a decrease of ― from the same quarter last year. In Q, Lexington Biosciences's net income was C$-65.60K. See Lexington Biosciences’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	-	C$ 0.00	C$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	C$ 189.34K	C$ 175.97K	C$ 324.24K	C$ -480.62K	C$ 533.53K	C$ 2.34M
Operating Income	C$ -189.34K	C$ -175.97K	C$ -324.24K	C$ -480.62K	C$ -533.53K	C$ -2.34M
Net Non Operating Interest Income Expense	-	-	-	-	C$ -120.79K	C$ 0.00
Other Income Expense	-	-	-	-	C$ -615.47K	-
Pretax Income	C$ -189.34K	C$ -175.97K	C$ -324.24K	C$ -480.62K	C$ -1.27M	C$ -2.34M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	C$ -189.34K	C$ -175.97K	C$ -324.24K	C$ -480.62K	C$ -1.27M	C$ -2.34M
Basic EPS	C$ 0.01	C$ 0.01	C$ 0.01	C$ 0.04	C$ -0.34	C$ -0.62
Diluted EPS	C$ 0.01	C$ 0.01	C$ 0.01	C$ 0.04	C$ -0.34	C$ -0.62
Basic Average Shares	C$ 109.83M	C$ 27.46M	C$ 27.46M	C$ 12.05M	C$ 3.79M	C$ 3.79M
Diluted Average Shares	C$ 109.83M	C$ 27.46M	C$ 27.46M	C$ 12.05M	C$ 3.79M	C$ 3.79M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	C$ 189.34K	C$ 175.97K	-	-	C$ 533.53K	C$ 2.34M
Net Income From Continuing And Discontinued Operation	C$ -189.34K	C$ -175.97K	C$ -324.24K	C$ -480.62K	C$ -1.27M	C$ -2.34M
Normalized Income	C$ -139.16K	C$ -129.34K	C$ -238.32K	C$ -480.62K	C$ -654.31K	C$ -2.34M
Interest Expense	-	-	-	-	C$ 120.79K	C$ 0.00
EBIT	C$ -189.34K	C$ -175.97K	C$ -324.24K	C$ -480.62K	C$ -1.15M	C$ -2.34M
EBITDA	C$ -189.34K	C$ -175.97K	C$ -324.24K	C$ -480.62K	C$ -1.15M	C$ -2.34M

Currency in CAD

Lexington Biosciences Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing